The clinical trial of key Alzheimer's drug solanezumab has failed, Eli Lilly has announced But this is not the end for beta amyloid theory, one expert says. Eli Lilly made the announcement yesterday that solanezumab did not slow down cognitive decline in patients with Alzheimer’s compared to those who took placebo. Solanezumab targeted beta amyloid—the protein that
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.